Acrylonitrile Industry Outlook in China to 2019

Private Companies Dominate the Acrylonitrile sector in China

Substantial growth is expected in the production of Acrylonitrile in China. Private companies have been dominating the Acrylonitrile sector in China in the recent past. The major companies in the region are China National Petroleum Corporation, China Petrochemical Corporation, China Wanda Group, BP p.l.c. and China Petroleum & Chemical Corporation. Together these companies accounted for 93.3% of the Acrylonitrile capacity in China in 2014.

GlobalData’s Acrylonitrile Industry Outlook in China to 2019 report provides historical and forecast market size, demand and production forecasts, end-use demand details, price trends, trade balance data, and company shares of the country’s leading producers to provide comprehensive coverage of all parameters of the industry.

Single User Price: $1000

Advertisements

COP21 – A Crucial Pathway towards Attaining a New Universal Climate Agreement

COP21 Pledges Require Significant Work to Achieve Climate Change Goals

195 countries and the European Union have consented to a global climate change agreement to limit the rise in global temperature to 2°C by 2100, at the United Nations’ 21st Conference of the Parties (COP21). The major focus areas of the conference included decreasing Greenhouse Gas (GHG) emissions and promoting sustainable development (UNDP, 2015). Overall, the world is taking seriously the need to assuage the effects of climate change. Despite this, COP21’s biggest obstacle will likely be reaching a committed and legally binding agreement to tackle climate imbalance that works for all countries, particularly considering the financial costs of implementing environmentally-friendly policies.

GlobalData’s COP21 – a Crucial Pathway towards Attaining a New Universal Climate Agreement, report provides an overview of Intended Nationally Determined Contribution submissions and efforts undertaken by major countries to combat global climatic conditions during the United Nations’ 21st Conference of the Parties (COP21).

Single User Price: $500

H2 Global Capacity and Capital Expenditure Outlook for LNG Terminals

North America and Asia to Drive Global LNG Industry Growth with Record Capital Spending

The global LNG industry is poised for substantial growth over the next four years as North America enters in to the LNG export market while Asia will continue to increase its share of LNG imports. Booming unconventional gas production has transformed US from LNG importer to exporter. Of the 67 planned liquefaction terminals by 2019, 32 alone are slated to come online in the US and Canada. The North American liquefaction and regasification capacities have increased marginally in the last quarter.

GlobalData’s latest report H2 Global Capacity and Capital Expenditure Outlook for LNG Terminals provides historical LNG liquefaction and regasification capacities data from 2009 to 2014, forecasts up to 2019. The report also includes details of all the planned, stalled and cancelled LNG liquefaction and regasification projects in the world up to 2019.

Single User Price: $1,500

Deep Brain Stimulators – Medical Devices Pipeline Assessment, 2015

A Deep Brain Stimulator (DBS) is an impulse generating device which is implanted surgically to send electrical impulses to specific parts of the brain. Deep Brain Stimulators have markedly increased in popularity in the recent past. Who are the major players involved in the development of DBS devices? Are you aware of the key ongoing trials and recent developments in the segment?

GlobalData’s latest report Deep Brain Stimulators – Medical Devices Pipeline Assessment, 2015 provides a detailed overview and comprehensive information on the pipeline products with comparative analysis of the products at various stages of development.

Single User Price: $4,000

COPD Therapeutics in Major Developed Markets in 2021

Global Chronic Obstructive Pulmonary Disease Treatment Market to Hit $11.2 Billion by 2021

The global treatment market for Chronic Obstructive Pulmonary Disease (COPD) will rise steadily from $9.2 billion in 2014 to $11.2 billion in 2021, at a compound annual growth rate of 2.9%. The COPD therapeutics market landscape over the forecast period will be characterized by the sales erosion of leading brands. Currently, the market is dominated by three brands, namely Pfizer’s Spiriva, GlaxoSmithKline’s (GSK’s) Advair and AstraZeneca’s Symbicort, which have all generated multi-billion dollar revenues to date. The patents for these leading brands have either expired or will do very soon, leaving the market open to generic competition, which will impact negatively on these brands’ sales figures. The market, which used to be dominated by only a few brands, will become more fragmented and will see the introduction of various brands with similar characteristics.

GBI Research’s COPD Therapeutics in Major Developed Markets in 2021 – Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands report provides analysis of the Chronic Obstructive Pulmonary Disease (COPD) treatment pipeline, by stage of development, molecule type, and molecular target. It provides information on the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.

Single User Price: $4,995

Healthcare: Biobanking Industry

Biobanks are an essential part of the infrastructure underpinning life sciences and biotechnology. They consist of service providers and repositories of the living cells, the genomes of the organism and information relating to heredity and the functions of biological systems. Diseases are being increasingly studied at a fundamental level, to comprehend the involvement of genes and their role in disease genesis. This growing interest in understanding the involvement of genes in diseases and collecting human biological materials for storage and analysis has led to the development of biobanks. The importance of biobanks lies in determining the most effective way to store that information and make it available when required.

CBR Pharma’s latest report “Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future” discusses fundamental concepts in biobanking and recent technology advancements in the field. The report also describes ethical and regulatory concerns in biobanking as well as the economic challenges and opportunities surrounding this industry.

Single User Price: $2,995 – pages: 118

Compression Therapy to 2021

While Western nations, such as the US and Germany, currently dominate the market, emerging economies are expected to see the fastest growth over the forecast period. Despite the US being the biggest market in the treatment area with a value of $1.4 billion in 2014, the Asia-Pacific (APAC) region, which consists of Japan, China, and India, is expected to become the fastest growing market. Japan had the largest share of the APAC compression therapy market with a 41% stake in 2014, but this will fall to 29% by the end of the forecast period as the other markets experience faster growth. China and India are forecast to claim 40% and 31% of the APAC market, respectively, by 2021.

GlobalData’s MediPoint: Compression Therapy – Global Analysis and Market Forecasts report provides analysis of the compression therapy space across the 10 major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, China and India, including annualized market data from 2014 and forecast until 2021.

Single User Price: $6,495 – Pages: 289